ARX, PDX1, ISL1, and CDX2 Expression Distinguishes 5 Subgroups of Pancreatic Neuroendocrine Tumors With Correlations to Histology, Hormone Expression, and Outcome

被引:4
作者
Moser, Elisa [1 ]
Ura, Ayako [1 ]
Vogel, Loreen [2 ]
Steiger, Katja [1 ]
Mogler, Carolin [1 ]
Evert, Matthias [3 ]
Markl, Bruno [4 ]
Scheidhauer, Klemens [2 ]
Martignoni, Marc [5 ]
Friess, Helmut [5 ]
von Werder, Alexander [6 ]
Marinoni, Ilaria [7 ]
Perren, Aurel [7 ]
Kloppel, Gunter [1 ]
Kasajima, Atsuko [1 ]
机构
[1] Tech Univ Munich, TUM Sch Med & Hlth, Dept Pathol, Munich, Germany
[2] Tech Univ Munich, TUM Sch Med & Hlth, Dept Nucl Med, Munich, Germany
[3] Univ Regensburg, Inst Pathol, Regensburg, Bavaria, Germany
[4] Univ Augsburg, Med Fac Augsburg, Dept Pathol, Augsburg, Bavaria, Germany
[5] Tech Univ Munich, TUM Sch Med & Hlth, Dept Surg, Munich, Germany
[6] Tech Univ Munich, TUM Sch Med & Hlth, Dept Internal Med 2, Munich, Germany
[7] Univ Bern, Inst Tissue Med & Pathol, Bern, Switzerland
关键词
hormone expression; outcome; PanNETs; subgroups; transcription factors; MARKER; CELLS;
D O I
10.1016/j.modpat.2024.100595
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Many pancreatic neuroendocrine tumors (PanNETs) fall into 2 major prognostic subtypes based on DAXX/ATRX-induced alternative lengthening of telomerase phenotype and alpha- and beta-cell-like epigenomic profiles. However, these PanNETs are still flanked by other PanNETs that do not fit into either subtype. Furthermore, despite advanced genotyping, PanNETs are generally not well-characterized in terms of their histologic and hormonal phenotypes. We aimed to identify new subgroups of PanNETs by extending the currently used transcription factor signatures and investigating their correlation with histologic, hormonal, molecular, and prognostic findings. One hundred eighty-five PanNETs (nonfunctioning 165 and functioning 20), resected between 1996 and 2023, were classified into 5 subgroups (A1, A2, B, C, and D) by cluster analysis based on ARX, PDX1, islet-1 (ISL1), and CDX2 expressions and correlated with trabecular vs solid histology, expression of insulin, glucagon, polypeptide (PP), somatostatin, serotonin, gastrin, calcitonin, adrenocorticotropic hormone (ACTH), DAXX/ATRX, MEN1, and alternative lengthening of telomerase status by fluorescence in situ hybridization, and disease-free survival. A1 (46%, ARX+/ISL1+/PDX1-/CDX2-) and A2 (15%, ARX+/ISL1+/PDX1+/CDX2-) showed trabecular histology and glucagon/PP expression, with A2 also showing gastrin expression. B (18%, PDX1+/ISL1+/ARX-/CDX2-) showed solid histology, insulin, and somatostatin expression (P < .001). It included all insulinomas and had the best outcome (P < .01). C (15%, ARX-/PDX1-/ISL1-/CDX2-) showed solid histology and frequent expression of serotonin, calcitonin, and ACTH. D (5%, PDX1+/CDX2+/ISL1-/ARX-) showed solid histology, expressed ACTH/serotonin, and was an independent poor prognosticator (P < .01). Differential expressions of ARX, PDX1, ISL1, and CDX2 stratified PanNETs into 5 subgroups with different histologies, hormone expressions, and outcomes. Subgroups A1 and A2 resembled the alpha-cell-like type, and subgroup B, the beta-cell-like type. Subgroup C with almost no transcription factor signature was unclear in cell lineage, whereas the PDX+/CDX2+ signature of subgroup D suggested a pancreatic/intestinal cell lineage. Assigning PanNETs to the subgroups may help establish the diagnosis, predict the outcome, and guide the treatment. (c) 2024 THE AUTHORS. Published by Elsevier Inc. on behalf of the United States & Canadian Academy of Pathology. This is an open access article under the CC BY license (http://creativecommons.org/ licenses/by/4.0/).
引用
收藏
页数:10
相关论文
共 29 条
  • [21] Serotonin expression in pancreatic neuroendocrine tumors correlates with a trabecular histologic pattern and large duct involvement
    McCall, Chad M.
    Shi, Chanjuan
    Klein, Alison P.
    Konukiewitz, Bjoern
    Edil, Barish H.
    Ellison, Trevor A.
    Wolfgang, Christopher L.
    Schulick, Richard D.
    Kloeppel, Guenter
    Hruban, Ralph H.
    [J]. HUMAN PATHOLOGY, 2012, 43 (08) : 1169 - 1176
  • [22] Predicting recurrence in pancreatic neuroendocrine tumours: role of ARX and alternative lengthening of telomeres (ALT)
    Neyaz, Azfar
    Crotty, Rory
    Rickelt, Steffen
    Pankaj, Amaya
    Stojanova, Marija
    Michelakos, Theodoros P.
    Sekigami, Yurie
    Kontos, Filippos
    Parrack, Paige H.
    Patil, Deepa T.
    Heaphy, Christopher M.
    Ferrone, Cristina R.
    Deshpande, Vikram
    [J]. HISTOPATHOLOGY, 2023, 83 (04) : 546 - 558
  • [23] DAXX/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumors
    Park, Joo Kyung
    Paik, Woo Hyun
    Lee, Kyoungbun
    Ryu, Ji Kon
    Lee, Sang Hyub
    Kim, Yong-Tae
    [J]. ONCOTARGET, 2017, 8 (30) : 49796 - 49806
  • [24] Whole-genome landscape of pancreatic neuroendocrine tumours
    Scarpa, Aldo
    Chang, David K.
    Nones, Katia
    Corbo, Vincenzo
    Patch, Ann-Marie
    Bailey, Peter
    Lawlor, Rita T.
    Johns, Amber L.
    Miller, David K.
    Mafficini, Andrea
    Rusev, Borislav
    Scardoni, Maria
    Antonello, Davide
    Barbi, Stefano
    Sikora, Katarzyna O.
    Cingarlini, Sara
    Vicentini, Caterina
    McKay, Skye
    Quinn, Michael C. J.
    Bruxner, Timothy J. C.
    Christ, Angelika N.
    Harliwong, Ivon
    Idrisoglu, Senel
    McLean, Suzanne
    Nourse, Craig
    Nourbakhsh, Ehsan
    Wilson, Peter J.
    Anderson, Matthew J.
    Fink, J. Lynn
    Newell, Felicity
    Waddell, Nick
    Holmes, Oliver
    Kazakoff, Stephen H.
    Leonard, Conrad
    Wood, Scott
    Xu, Qinying
    Nagaraj, Shivashankar Hiriyur
    Amato, Eliana
    Dalai, Irene
    Bersanif, Samantha
    Cataldo, Ivana
    Tos, Angelo P. Dei
    Capelli, Paola
    Davi, Maria Vittoria
    Landoni, Luca
    Malpaga, Anna
    Miotto, Marco
    Whitehall, Vicki L. J.
    Leggett, Barbara A.
    Harris, Janelle L.
    [J]. NATURE, 2017, 543 (7643) : 65 - +
  • [25] Islet 1 (Isl1) expression is a reliable marker for pancreatic endocrine tumors and their metastases
    Schmitt, Anja M.
    Riniker, Florian
    Anlauf, Martin
    Schmid, Sonja
    Soltermann, Alex
    Moch, Holger
    Heitz, Philipp U.
    Kloeppel, Guenther
    Komminoth, Paul
    Perren, Aurel
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2008, 32 (03) : 420 - 425
  • [26] Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors
    Singhi, Aatur D.
    Liu, Ta-Chiang
    Roncaioli, Justin L.
    Cao, Dengfeng
    Zeh, Herbert J.
    Zureikat, Amer H.
    Tsung, Allan
    Marsh, J. Wallis
    Lee, Kenneth K.
    Hogg, Melissa E.
    Bahary, Nathan
    Brand, Randall E.
    McGrath, Kevin M.
    Slivka, Adam
    Cressman, Kristi L.
    Fuhrer, Kimberly
    O'Sullivan, Roderick J.
    [J]. CLINICAL CANCER RESEARCH, 2017, 23 (02) : 600 - 609
  • [27] Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy
    Volante, Marco
    Brizzi, Maria Pia
    Faggiano, Antongiulio
    La Rosa, Stefano
    Rapa, Ida
    Ferrero, Anna
    Mansueto, Gelsomina
    Righi, Luisella
    Garancini, Silvana
    Capella, Carlo
    De Rosa, Gaetano
    Dogliotti, Luigi
    Colao, Annamaria
    Papotti, Mauro
    [J]. MODERN PATHOLOGY, 2007, 20 (11) : 1172 - 1182
  • [28] Morphologic Variants of Pancreatic Neuroendocrine Tumors: Clinicopathologic Analysis and Prognostic Stratification
    Xue, Yue
    Reid, Michelle D.
    Pehlivanoglu, Burcin
    Obeng, Rebecca C.
    Jiang, Hongmei
    Memis, Bahar
    Lui, Shu K.
    Sarmiento, Juan
    Kooby, David
    Maithel, Shishir K.
    El-Rayes, Bassel
    Basturk, Olca
    Adsay, Volkan
    [J]. ENDOCRINE PATHOLOGY, 2020, 31 (03) : 239 - 253
  • [29] Metastatic insulinoma: exploration from clinicopathological signatures and genetic characteristics
    Zhang, Jingcheng
    Jiang, Rui
    Hong, Xiafei
    Wu, Huanwen
    Han, Xianlin
    Wu, Wenming
    [J]. FRONTIERS IN ONCOLOGY, 2023, 13